Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane/tazobactam
- PMID: 28363945
- PMCID: PMC5388004
- DOI: 10.1136/bcr-2016-217005
Successful treatment of multidrug-resistant Pseudomonas aeruginosa pubic symphysis osteomyelitis with ceftolozane/tazobactam
Abstract
New antibiotic options are needed for the treatment of multidrug-resistant (MDR) Pseudomonas infections. We present a case of a man aged 64 years with a bladder fistula due to radiation, ultimately causing osteomyelitis of the pubic symphysis. Repeated antibiotic courses, without correcting the fistula, resulted in infection with MDR Pseudomonas aeruginosa. He was successfully treated for his osteomyelitis through cystectomy, aggressive debridement and a prolonged course of antimicrobials directed at the MDR Pseudomonas isolate.
2017 BMJ Publishing Group Ltd.
Conflict of interest statement
Figures


Similar articles
-
Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.Int J Antimicrob Agents. 2018 Mar;51(3):498-502. doi: 10.1016/j.ijantimicag.2017.11.003. Epub 2017 Nov 20. Int J Antimicrob Agents. 2018. PMID: 29158144
-
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.Pharmacotherapy. 2016 Oct;36(10):e154-e159. doi: 10.1002/phar.1825. Epub 2016 Sep 1. Pharmacotherapy. 2016. PMID: 27522066
-
Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.J Antimicrob Chemother. 2017 Sep 1;72(9):2678-2679. doi: 10.1093/jac/dkx172. J Antimicrob Chemother. 2017. PMID: 28575437 No abstract available.
-
Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.Expert Rev Anti Infect Ther. 2017 Sep;15(9):861-871. doi: 10.1080/14787210.2017.1367666. Epub 2017 Aug 18. Expert Rev Anti Infect Ther. 2017. PMID: 28803496 Review.
-
Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Ann Pharmacother. 2015 Sep;49(9):1046-56. doi: 10.1177/1060028015593293. Epub 2015 Jul 9. Ann Pharmacother. 2015. PMID: 26160970 Review.
Cited by
-
Postoperative soft-tissue infection due to multidrug-resistant Pseudomonas aeruginosa: usefulness of ceftolozane-tazobactam.Rev Esp Quimioter. 2018 Aug;31(4):374-375. Epub 2018 Jul 9. Rev Esp Quimioter. 2018. PMID: 30014680 Free PMC article. No abstract available.
-
Ceftolozane-tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series.Ther Adv Drug Saf. 2019 Jul 8;11:2042098619862083. doi: 10.1177/2042098619862083. eCollection 2019. Ther Adv Drug Saf. 2019. PMID: 31312424 Free PMC article.
-
Outpatient Parenteral Antimicrobial Therapy With Ceftolozane/Tazobactam via Continuous Infusion for Multidrug-Resistant Pseudomonas aeruginosa Osteomyelitis.Open Forum Infect Dis. 2020 Sep 15;7(11):ofaa409. doi: 10.1093/ofid/ofaa409. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33204747 Free PMC article.
-
Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa.BMJ Case Rep. 2018 Jan 5;2018:bcr2017223202. doi: 10.1136/bcr-2017-223202. BMJ Case Rep. 2018. PMID: 29305368 Free PMC article.
-
Real-world use of ceftolozane/tazobactam: a systematic literature review.Antimicrob Resist Infect Control. 2021 Apr 8;10(1):68. doi: 10.1186/s13756-021-00933-8. Antimicrob Resist Infect Control. 2021. PMID: 33832545 Free PMC article.
References
-
- Mohler JL, Armstrong AJ, Bahnson RR et al. . Prostate cancer, version 1.2016. J Natl Compr Canc Netw 2016;14:19–30. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical